on industry trends and bringing new treatments to market
We caught up with the company once more and put a few more questions to CEO Sebastian Coppe about the forthcoming CPhI North America being held from May 7-9 at the Pennsylvania Convention Center.
As a company which has launched to address strategic challenges in the biopharma industry today, where do you see the value for those attending this popular and well-attended conference?
CPhI serves as a significant platform for observing emerging trends that are reshaping approaches to biopharma R&D and it allows us to address important topics like patient-centricity and objectives of regulatory agencies while putting forward ways to accelerate the delivery of new treatments to market.
How does your company approach research and development to drive innovation and meet evolving customer needs?
One2Treat’s approach to research and development (R&D) is deeply rooted in addressing the shortcomings of conventional methods in clinical trial research. Our founder, Marc Buyse, recognized the limitations of traditional approaches, which often narrowly focused on single primary criterion for evaluating new treatments. This narrow lens often disregarded valuable patient data and potential therapeutic benefits. To bridge these gaps, One2Treat embraces a holistic and patient-centric methodology.
At the core of our R&D strategy is the development of the Generalized Pairwise Comparisons (GPC) statistical method. This innovative approach enables a comprehensive analysis of treatment effects across multiple clinically relevant outcomes, offering a fuller picture of a treatment’s potential benefits. By broadening the scope of analysis, we aim to empower the biopharma industry to incorporate patient needs into every step of the treatment assessment process, starting from the clinical trial design.
Moreover, our commitment to democratizing access to advanced statistical analysis is evident in our software development efforts. We create user-friendly tools focused on comprehensive benefit-risk analysis, making advanced statistical analysis accessible to users irrespective of their programming or statistical expertise. By emphasizing simplicity and efficiency, we strive to make advanced statistical analysis a standard part of clinical research, empowering more informed treatment decisions.
How does your company stay ahead of industry trends and developments in the pharmaceutical sector?
The company is dedicated to transforming clinical research by making trials more patient-centric and data-informed (using information from past trials as well as potentially real-world evidence). Leveraging our software to identify and select the most patient-relevant outcomes, we not only improve the precision of clinical studies but also accelerate the path to market for promising treatments. Indeed, utilizing more of the collected patient data enables us to significantly reduce the required sample size, thereby shortening recruitment timelines. Our ongoing commitment to enhancing drug development processes ensures that every piece of patient data is valued, and every potential treatment is thoroughly assessed, incorporating all key patient needs. Ultimately, our approach aims to bridge the gap between clinical research, market access and health technology assessments, facilitating faster delivery of globally beneficial treatments to patients.